If My Insurance Won't Cover Lu-177 PSMA Therapy for PSMA-Positive Prostate Cancer, What Are My Realistic Financial Options?

Finding out that Lu-177 PSMA therapy may help slow your PSMA-positive prostate cancer is one kind of moment. Finding out your insurance will not pay for it is another.

An insurance denial is not final. There are real, documented pathways that men have used to access this therapy. Some take time and paperwork. Some require creative thinking about treatment location. But none require giving up.

This guide walks through each pathway in plain language. The goal is to help you prepare for your next conversation with your doctor, so you know what questions to ask and what options exist.

Why Insurers Sometimes Say No

Lu-177 PSMA therapy, known by the brand name Pluvicto in the United States, received FDA approval in March 2022 for adults with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC). The Prostate Cancer Foundation notes that approval was later expanded to allow earlier use of this therapy for eligible patients, before chemotherapy becomes necessary.

FDA approval does not automatically mean your insurer will cover the treatment. Denials happen for several reasons:

• The insurer classified the treatment as not medically necessary based on its own internal criteria, which may differ from your oncologist's recommendation
• Your treatment plan did not follow a required sequence of prior therapies, sometimes called step therapy
• The treating facility or physician is out of your plan's network
• Medical necessity documentation submitted to the insurer was missing or incomplete
• The insurer is applying outdated coverage criteria that do not reflect current oncology guidelines

Each of these denial reasons can be challenged. The process takes time and careful documentation, but it is worth pursuing before you look at other options.

Your First and Most Important Move: Appeal the Denial

Under U.S. federal law, when an insurer denies a claim it must tell you in writing why and explain how you can appeal. The American Cancer Society explains that you have two levels of appeal rights.

The internal appeal is your first step. You formally ask the insurance company to review its own decision. This works best when your submission includes:

• A detailed letter of medical necessity from your oncologist, written for your individual clinical situation
• Your PSMA PET scan results, confirming PSMA-positive disease
• Published clinical guidelines such as NCCN guidelines that support use of this therapy for men with your diagnosis and treatment history
• Published clinical trial data that formed the basis for FDA approval of this therapy in mCRPC, including results from the VISION trial

The external review is available if the internal appeal fails. You can request an independent review by an organization completely outside your insurance plan. In most states, this is a legal right, and the external reviewer's decision is typically binding on the insurer.

Some states also run Consumer Assistance Programs that can help you file an appeal at no cost. Contact your state insurance commissioner's office to ask whether one exists in your state.

Ask your oncologist's office to assign a patient financial advocate or social worker to support this process. They know what documentation insurers typically need and what language makes appeals more likely to succeed. The sooner you involve them, the better, since most insurance plans have tight deadlines for appeals.

To strengthen an appeal letter, read our overview of who qualifies for Lu-177 PSMA therapy.

Manufacturer Patient Assistance Programs

While an appeal is in progress or if it does not succeed, the company that makes Pluvicto has programs that may help reduce your costs.

AAA PatientCONNECT is the patient support program run by Advanced Accelerator Applications (a Novartis company). It offers two main types of help:

• Co-pay assistance: For patients who have commercial (private) insurance but still face high out-of-pocket costs, this program may help reduce what you pay per treatment cycle. This benefit applies only to patients with commercial insurance. Patients on Medicare, Medicaid, or other federal or state programs cannot use this benefit.
• Novartis Patient Assistance Foundation (NPAF): For patients who are uninsured or underinsured and meet income eligibility criteria, this foundation may be able to provide access to the medication at no cost. Eligibility requirements apply and are assessed case by case.

To learn whether you qualify, call Novartis Patient Support at 1-844-638-7222, Monday through Friday, 8 am to 8 pm Eastern time. Your oncologist's office can also begin an enrollment inquiry on your behalf through the program's clinical portal.

Keep in mind that manufacturer programs primarily help with the cost of the medication itself. Separate costs, including the infusion facility fee, PSMA PET scans, and follow-up lab work, may not be covered by the manufacturer program.

Independent Patient Assistance Organizations

Several non-profit organizations provide direct financial assistance to cancer patients, independent of any drug manufacturer. Contact these organizations at the same time you're working on an appeal and manufacturer programs. Do not treat them as a last resort.

The American Cancer Society's financial assistance resource guide includes these key organizations:

• Patient Advocate Foundation (PAF): Works directly with patients and their insurers to resolve coverage disputes. Also provides co-pay financial relief for eligible patients. Phone: 1-800-532-5274. Website: patientadvocate.org
• Patient Access Network Foundation (PANF): Provides financial assistance to under-insured patients with specific cancer diagnoses to help cover out-of-pocket treatment costs. Phone: 1-866-316-7263. Website: panfoundation.org
• HealthWell Foundation: Offers disease-specific funds for patients with certain diagnoses who face high out-of-pocket costs. Whether a relevant fund is currently open and accepting applications varies.
• CancerCare: Provides limited financial grants alongside free professional counseling and referral services for patients with any cancer diagnosis.

The Prostate Cancer Foundation's patient support page maintains an updated list of financial assistance resources specifically for men with prostate cancer, including links to these organizations and others whose enrollment periods open and close throughout the year. Check this page regularly since fund availability changes frequently.

When you contact any of these organizations, be prepared to describe your insurance situation, your diagnosis, and your current treatment status. The more specific you are, the faster a program coordinator can tell you whether you qualify and what the application process involves.

Clinical Trials: A Path to No-Cost Treatment

Participating in a clinical trial is a reliable way to access Lu-177 PSMA therapy without paying out of pocket. In most trials, the study drug is provided to participants at no charge. Some trials also cover costs related to required scans, laboratory tests, and follow-up visits that are part of the trial protocol.

Clinical trials currently recruiting for Lu-177 PSMA therapy are listed on the National Institutes of Health's ClinicalTrials.gov database. Search for the terms lutetium PSMA prostate cancer and filter by recruiting status and your location.

Before pursuing a trial, understand these practical realities:

• Trials have specific eligibility requirements. Most require a confirmed PSMA-positive scan, a defined number of prior treatments, and specific lab values. Ask the trial team about these requirements early before making any travel arrangements.
• Some trials use the standard FDA-approved therapy. Others are testing new versions, combinations, or treatment sequences. Your oncologist can help you identify which trial design best fits your current clinical situation.
• Travel costs to the trial site are generally your responsibility, though some trials offer stipends or partial travel reimbursement. Ask about this upfront and get a written answer.
• Expanded access programs, also called compassionate use, are separate from formal trials. They may allow access to a therapy outside of a trial context for patients who have run out of standard treatment options. Ask your oncologist whether your situation could qualify for expanded access consideration.

To understand what the most recent evidence shows about how this therapy may work for men with stage 4 prostate cancer, our article on the latest Lu-177 PSMA clinical trial results covers the key data.

Understanding Medicare and Medicaid Coverage

If you are on Medicare, coverage for Lu-177 PSMA therapy depends on how your specific plan classifies the treatment and where you receive it. Radioligand therapies in an outpatient clinical setting typically fall under Medicare Part B, which covers outpatient medical services, or Part D, which covers prescription drugs. The classification differs based on whether treatment takes place in a hospital outpatient department, a freestanding nuclear medicine facility, or a physician's office.

Before your first infusion, ask your oncology team whether the billing department has confirmed Medicare coverage for your specific plan and facility combination. Have this conversation before you receive treatment, not after the first bill arrives.

If Medicare denies coverage, you have the right to appeal through Medicare's multi-step appeals process. The Medicare Rights Center (medicarerights.org) offers free guidance to patients dealing with these disputes and can walk you through the process step by step.

Medicaid coverage for this therapy varies widely by state. Some state programs cover FDA-approved cancer therapies without restriction. Others require prior authorization, step therapy requirements, or have formularies that may limit access to newer treatments. Contact your state Medicaid program office directly to ask about your specific situation before assuming anything about coverage.

Seeking Treatment Outside the United States

For patients who have worked through U.S.-based options without success or who face long wait times before domestic access becomes available, traveling internationally for Lu-177 PSMA therapy is a realistic option that some men with advanced prostate cancer have pursued.

India has developed a growing infrastructure for this therapy, with established nuclear medicine centers that treat international patients. Cost reports show that per-cycle treatment costs in India are considerably lower than in the United States or Western Europe, though exact pricing varies by center, the number of cycles required, and each patient's individual clinical needs. Travel, accommodation, and follow-up care costs must also be part of any realistic total cost estimate.

Before going this route, work through the following questions carefully with your oncologist:

• Is the overseas treatment center accredited by an internationally recognized body?
• How will your home oncologist communicate and coordinate with the international team?
• Who will manage your monitoring, blood work, and any complications when you return home?
• What is the full estimated cost including round-trip travel and accommodation for the duration of treatment cycles?

Our article on why India is becoming a global destination for lutetium therapy provides broader context on how this treatment infrastructure has grown in the region and what international patients have experienced receiving care there.

Building the Right Support Team

The financial and administrative side of pursuing a high-cost cancer therapy can feel as overwhelming as the medical side. You do not have to manage it alone.

• Your oncologist's patient financial coordinator or social worker: Most major cancer centers have staff whose specific role is to help patients find financial pathways. Ask to be connected with this person early, ideally before an appeal deadline expires.
• A professional patient advocate: Independent patient advocates can manage appeals and assistance program processes on your behalf. Some work on a sliding scale or offer pro bono services for oncology patients. The Patient Advocate Foundation offers free case management services for eligible patients.
• Your state insurance commissioner's office: If you believe your insurer is applying unreasonable or outdated criteria, your state insurance department has the authority to investigate consumer complaints and, in some circumstances, intervene.
• Hospital financial counselors: Large cancer centers sometimes maintain institutional charity care or financial hardship funds that are not widely advertised. A financial counselor at the treating center can tell you whether any internal support options exist for your situation.

When to Talk to Your Doctor

Your oncologist is your most important ally in this process. Before taking any of the steps described in this guide, have a direct conversation with your care team. Some questions worth raising:

• Would you write a detailed letter of medical necessity for my insurance appeal?
• Are there clinical trials I currently qualify for that would provide this therapy at no cost?
• Does this practice have a patient financial navigator who can help me with appeals and assistance programs?
• Is international treatment a realistic option for my specific situation, and how would follow-up care be managed?

This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.